private investments into oncolytic virus companies in 2016 was nearly 17- fold higher than in the year 2010 .
Make an Enquiry : http :// www . marketresearchhub . com / enquiry . php ? type = enquiry & re pid = 943738
Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration ( intratumoral vs systemic ), higher cancer cell specific replication capacity , and longer persistence in vivo . Based on experience with several virus families over the last decades , a few virus families cristallized as well suitable backbones to carry more and more transgenes to express proteins or even single chain antibodies . This would position oncolytic viruses as independent therapeutics and could compete with immunooncology compounds and cancer vaccines .
This report „ The Oncolytic Virus Landscape 2017 : an analysis of pipeline , stakeholders , deals , industry trends & opportunities “ as of January 2017 brings you up-to-date regarding key players , key technologies , Oncolytic Virus projects , business deals and private and public financing rounds . The report analyzes the Oncolytic Virus pipeline and stakeholders in the field , especially among Big Pharma / Biotech and technology companies . The report highlights the value of oncolytic viruses in terms of partnering terms and conditions , venture and private financing and ( initial ) public offerings .
Ask For Discount : http :// www . marketresearchhub . com / report / theoncolytic-virus-landscape-2017-an-analysis-of-pipelinestakeholders-deals-industry-trends-opportunitiesreport . html # discount-form
Table of Contents 1 Executive Summary